Genmab A/S (GMAB) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello and welcome to the GenMAP's first quarter 2026 financial results conference call. As a reminder, this conference call is being recorded. During this telephone conference, you may be presented with forward-looking statements that include words such as beliefs, anticipates, plans or expects. Actual results may differ materially, for example, as a result of delayed or unsuccessful development projects. GenMAP is not under any obligation to update statements regarding the future, nor to confirm such statements in relation to actual results, unless this is required by law. Please also note that GenMap may hold your personal data as indicated by you as a part of our investor relations outreach activities in order to update you on GenMap going forward. Please refer to our website for more information on GenMap and our privacy policy. I would like to hand the conference over to our first speaker today, Jan van der Winkel. Please go ahead. Hello, and welcome to our financial results call for the first quarter of 2026. With me today is our Chief Financial Officer, Anthony Pagano, and our Chief Commercial Officer, Brad Bailey. For the Q&A, we will be joined by our Chief Medical Officer, Tai Yamadi, and our Chief Development Officer, Judith Klimowski. As noted, we will be making forward-looking statements, so please keep that in mind. Let's move to the first quarter highlights. In Q1, 2026, we continue to deliver strong financial performance and make focused progress against our strategic priorities. We grew total revenue by 25%, reflecting continued momentum across our portfolio. And importantly, we continue to invest with discipline in our medicines, in our pipeline, and in our future growth, fully aligned with our capital allocation priorities. Even with these strategic...